Bank Of Nova Scotia Cyma Bay Therapeutics, Inc. Transaction History

Bank Of Nova Scotia

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$5.88 - $9.59 $79,697 - $129,982	13,554 New	13,554 $118,000
Q3 2022 Nov 10, 2022	SELL	$2.77 - $4.25 $3,905 - $5,992	-1,410 Reduced 8.98%	14,286 $50,000
Q2 2022 Aug 08, 2022	BUY	$1.72 - $3.39 $26,997 - $53,209	15,696 New	15,696 $46,000
Q2 2022 Aug 05, 2022	SELL	$1.72 - $3.39 $28,600 - $56,368	-16,628 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$2.77 - $3.64 $5,642 - $7,414	2,037 Added 13.96%	16,628 $52,000
Q4 2021 Feb 11, 2022	BUY	$3.23 - $4.6 $47,128 - $67,118	14,591 New	14,591 $55,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

Stay updated on Bank Of Nova Scotia with notifications on news.